Definium Therapeutics
DFTX
248 hedge funds and large institutions have $1.47B invested in Definium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 82 increasing their positions, 53 reducing their positions, and 27 closing their positions.
284% more call options, than puts
Call options by funds: $32.5M | Put options by funds: $8.45M
156% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 27
141% more capital inflows, than outflows
Capital inflows: $379M | Capital outflows: $157M
55% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 53
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more funds holding
Funds holding: 209 → 248 (+39)
9.4% more ownership
Funds ownership: 68.89% → 78.29% (+9.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28M |
| 2 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$27.1M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
+$22.5M |
| 4 |
Janus Henderson Group
London,
|
+$19.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$30.1M |
| 2 |
Blackstone Inc
New York
|
-$26.3M |
| 3 |
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$14.1M |
| 4 |
Driehaus Capital Management
Chicago,
Illinois
|
-$10.6M |
| 5 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$10.6M |
DFTX Hedge Fund Activity: Q1 2026 in Review
248 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2026, worth a combined $1.47B — up 62% from $909M a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new DFTX positions and 27 closed out — a net gain of 42 holders — while 82 added to existing stakes and 53 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28M. The largest seller was Marshall Wace, cutting an estimated $30.1M.
- 248 institutional investors held Definium Therapeutics (DFTX) as of Q1 2026, up from 209 in Q4 2025.
- Funds reported $1.47B of Definium Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
- 69 funds opened new Definium Therapeutics positions in Q1 2026 and 27 closed out, a net change of +42 holders.
- The largest Definium Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $28M added.
- The largest Definium Therapeutics seller in Q1 2026 was Marshall Wace, an estimated $30.1M sold.
Based on aggregated 13F filings for Q1 2026.